SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nuvus Gro Corp – ‘1-U’ for 2/7/20

On:  Friday, 2/7/20, at 2:36pm ET   ·   For:  2/7/20   ·   Accession #:  1671132-20-1

Previous ‘1-U’:  ‘1-U’ on / for 11/14/19   ·   Next:  ‘1-U’ on 7/22/22 for 7/20/22   ·   Latest:  ‘1-U’ on 3/26/24 for 3/25/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/07/20  Nuvus Gro Corp                    1-U:9       2/07/20    1:10K

Current Report — Reg. A   —   Form 1-U
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 1-U         Current Report -- Reg. A                            HTML      8K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 1-U

 

CURRENT REPORT PURSUANT TO REGULATION A

 

 

Date of Report (Date of earliest event reported):

February 07, 2020

 

NUVUS GRO CORP.

(Exact name of issuer as specified in its charter)

 

Nevada

82-3156625

State of other jurisdiction of incorporation or

organization

(I.R.S. Employer Identification No.)

 

10901 Roosevelt Blvd, Suite 1000c, Saint Petersburg, FL 33716

(Full mailing address of principal executive offices)

 

(727) 474-1810

(Issuer’s telephone number, including area code)

 

Title of each class of securities issued pursuant to Regulation A:

Common Stock, $0.001 par value

 

 

 

 

Item 9. Other Events

Nuvus Gro Corp. (the "Company") has engaged in discussions with Pharmax LLC for a possible acquisition in whole or part by the Company. Pharmax is developer of novel cannabinoid delivery methods for dispensing effective dose concentrations to treat different human diseases, OTC drug formulations, nutraceuticals and pharmaceutical research. Pharmax’s research and development includes specific delivery devices to treat chronic pain, developing therapeutic compounds and drug delivery from cannabinoid platform for various diseases. Pharmax’s consumer division. Promed Biosciences, includes nutraceuticals which provides CBD products in Isolate or Full spectrum to address the preferences of the consumer.

 

Exhibits

 

None


SIGNATURES

 

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

 

 

 

NUVUS GRO CORP.

 

 

 

 

 

 

 

 

Date:

February 07, 2020

 

By:

/s/ John Varghese

 

 

 

 

John Varghese, Acting Chief Executive Officer

 

Pursuant to the requirements of Regulation A, this report has been signed below by the following persons on behalf of the issuer and in the capacities and on the dates indicated.

 


Dates Referenced Herein

This ‘1-U’ Filing    Date    Other Filings
Filed on / For Period end:2/7/20None on these Dates
 List all Filings 
Top
Filing Submission 0001671132-20-000001   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 5:40:27.1am ET